Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. announced that it will present a poster on the three-year overall survival data for botensilimab (BOT) combined with balstilimab (BAL) at the IGCS Annual Global Meeting in 2026. This study focuses on recurrent ovarian cancer and highlights the company's commitment to advancing immuno-oncology treatments. The event will occur in Montreal, Canada.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus is presenting promising three-year survival data.
  • The study involves innovative immuno-oncology treatments.
  • The presentation will take place at a significant international meeting.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Botensilimab
Phase 1 · Pancreatic Cancer Metastatic

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada. The presentation will feature results from the recurre

Frequently Asked Questions

What data will Agenus present at IGCS 2026?

Agenus will present three-year overall survival data for botensilimab and balstilimab.

When is the IGCS Annual Global Meeting?

The IGCS Annual Global Meeting will take place from October 1 to 3, 2026.

Where will the IGCS meeting be held?

The meeting will be held in Montreal, Canada.

What is botensilimab?

Botensilimab is an Fc-enhanced multifunctional anti-CTLA-4 antibody.

What type of cancer is being studied?

The study focuses on recurrent ovarian cancer.

ShareAdd on Google
Tags: AGEN Viatris Investor Conferences Healthcare Agenus botensilimab balstilimab ovarian cancer IGCS 2026
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~1 mo
High dilution risk
Lead asset
BotensilimabPhase 1
Pancreatic Cancer Metastatic →

Catalyst track record

+52%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →